GlassScriptPhysician profile
Henry A Mata
NPI 1689777286
$19,204.42
in general payments reported to CMS, 2019-2025
68 companies · $3,371 in 2025
The $3,371 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,461 · 2020: $1,850 · 2021: $2,885 · 2022: $2,473 · 2023: $2,854 · 2024: $3,310 · 2025: $3,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,528 · Education: $7.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,527.84 |
| Education | $7.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,328.53 | 2021-2025 | Freestyle Libre 3, Cardiomems, Eterna |
| Novo Nordisk INC | $1,905.63 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,553.05 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $1,291.14 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $1,055.38 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $960.87 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $879.32 | 2021-2025 | |
| Abbvie INC. | $791.35 | 2019-2025 | |
| Glaxosmithkline, LLC. | $674.60 | 2019-2025 | Shingrix, Arexvy, Fluarix Quadrivalent |
| Teva Pharmaceuticals USA, INC. | $622.78 | 2019-2022 | |
| Optinose US, INC. | $614.65 | 2019-2025 | |
| Amarin Pharma, INC. | $518.42 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $452.75 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Pfizer INC. | $433.71 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $325.32 | 2019-2023 | Xarelto |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Mata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.